Directorate Change

RNS Number : 7430S
Advanced Medical Solutions Grp PLC
12 November 2013

12 November 2013


Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


Board Change


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces the appointment of Peter Allen as a Non-Executive Director effective from 4 December 2013. He will then become Non-Executive Chairman from 1 January 2014, replacing Dr. Don Evans who will retire from the Board on 31 December 2013.


Mr. Allen, aged 57, has extensive experience in the healthcare industry, having held key senior positions in a number of companies, playing a significant role in their development. This includes 12 years at Celltech Group plc (1992-2004) as CFO and Deputy CEO, 5 years as Chairman (since 2007) and interim CEO (2010-11) of ProStrakan Group plc, and 3 years as Chairman of Proximagen Neurosciences plc (2009-12). All of these companies, through a mix of organic growth, acquisitions and partnership agreements, saw significant increases in shareholder value during the periods in question.


Mr. Allen is currently Non-Executive Chairman of LSE listed Future plc and AIM listed Clinigen plc, as well as privately owned companies Chroma Therapeutics Limited and ProStrakan Group plc, although he will be stepping down as Non-Executive Chairman of the latter on 31 December 2013. Mr. Allen is also a Non-Executive Director of LSE listed Mecom plc, AIM listed Scancell plc and privately owned Oxford Nanopore Technologies Limited. He is a qualified chartered accountant.


Dr. Don Evans, Non-Executive Chairman of AMS, commented: “We are delighted to welcome Peter to the Board, firstly as a Non-Executive Director and then as my replacement at the beginning of next year. His significant experience of driving significant value creation at a number of healthcare companies, in both executive and non-executive roles, will be invaluable in the next stage of AMS’s growth.”


Save as disclosed below, there are no additional disclosures to be made in accordance with paragraph (g) of Schedule 2 of the AIM Rules in relation to Peter Allen.


Mr. Allen holds or has held directorships in the five years preceding his appointment at AMS as follows:


Current directorships:

·      Chroma Therapeutics Limited

·      Clinigen Group plc

·      Future plc

·      Mecom plc

·      Oxford Nanopore Technologies Limited

·      Prostrakan Group plc

·      Scancell plc

·      Macrotarg Limited

·      St. Mary’s School (Calne)

·      St. Mary’s School (Calne) Limited

·      The Calne Foundation Trust


Past directorships

·      Abacus Group Limited

·      Acambis plc

·      Alpha 3 Manufacturing Limited

·      Avnet Logistics Limited

·      Deltron Electronics Limited

·      Deltron Hawnt Limited

·      Deltron Holdings Limited

·      Deltron UK Limited

·      Dem Manufacturing Limited

·      ECC Distribution Limited

·      Lie Low Limited

·      Micromark Electronics Limited

·      Proximagen Neurosciences plc

·      Quiller Electronics Limited

·      Quiller Holdings Limited

·      Roxburgh Foxhills Limited

·      TMO Renewables Limited

·      Trident Microsystems Limited


– ends –


For further information, please visit or contact:


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Tavistock Communications

Tel: +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn

Investec Bank plc

Tel: +44 (0) 20 7597 5970

Gary Clarence / Daniel Adams / Patrick Robb


About Advanced Medical Solutions Group plc


Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.


AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer (“OEM”) customers around the world, but the majority of the Group’s revenues now come from its own brands – ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.


AMS’s products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.


With 450 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS’s products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.


This information is provided by RNS
The company news service from the London Stock Exchange